Continuously evaluating innovative ways to overcome diseases
The FDA has granted ONC201 Fast Track Designation for the treatment of adult recurrent H3 K27M-mutant high-grade glioma, Rare Pediatric Disease Designation for treatment of H3 K27M-mutant glioma, and Orphan Drug Designations for the treatment of glioblastoma and for the treatment of malignant glioma.
ONC201Phase 2Phase 2 (Mid)
ONC201 is in a phase 2 trial to treat Neuroendocrine Tumors (Pheochromocytoma/paraganglioma).
ONC206Phase 1Phase 1 (Mid)
The first-in-human ONC206 clinical trial for adults with recurrent primary central nervous system tumors is ongoing at the National Institute of Health.
Preclinical efficacy data generated using CMX521 as a potential prophylactic and treatment of SARS-CoV-2 (COVID-19) infection in collaboration and the Rapidly Emerging Antiviral Drug Development Initiative (READDI)
A $3.4 million grant awarded to Brown University supports completion of ONC212 IND-enabling studies and a first-in-human clinical trial.